Lipoprotein(a): Understanding Your Genetic Cardiovascular Risk

This test measures how much Lp(a) is circulating in your blood. Lp(a) stands for lipoprotein(a); on results and in searches you will also see it written without brackets, as lpa, or as lipoprotein a. It is always the same particle: a cargo of cholesterol wrapped in exactly one molecule of apolipoprotein B, just as in LDL, but with a second protein bolted onto it: apolipoprotein(a). That extra protein closely resembles plasminogen, the substance that helps dissolve blood clots. Lp(a) is therefore two things at once: a particle that can lodge in the artery wall, and a particle that works against the clearing of clots.

The decisive word for this value is predisposition. The LPA gene comes in variants with more or fewer so-called KIV-2 repeats. Few repeats means a small apo(a) protein, and that goes together with a higher Lp(a) in the blood. This inherited predisposition explains more than 90 percent of the difference between people and is fixed from birth. The result you hold today, you already had at thirty. It did not arise from years of too much butter or too little walking. Where your cholesterol climbs slowly across the decades and steps up around midlife, Lp(a) does nothing at all: it stands still.

Finally, watch the unit, especially if you keep older results. Your value here is given in g/l. That is a measure of weight, and 0.30 g/l is the same as 30 mg/dl, the unit you meet in international literature. There is also nmol/l, which counts particles rather than weight and is preferred internationally. Because the apo(a) protein is much larger in one person than in another, there is no reliable fixed conversion between the two. So a result from years ago at another laboratory cannot simply be laid alongside this one: compare only within the same unit, and let your doctor look with you if you are unsure.

Many people over fifty who read this result are already taking a cholesterol-lowering drug. The assumption is an easy one to make: my cholesterol is being treated, so this must be covered too. It is not, and it is the single most important thing to take from this page. A statin lowers your LDL cholesterol powerfully, but it has no grip at all on Lp(a). In fact Lp(a) rises slightly on a statin, by roughly ten to twenty percent. Your statin does its work on a different number, and that work remains entirely worthwhile. It simply does not cover this one.

Why that matters: Lp(a) is an independent, causal risk factor for cardiovascular disease. Risk climbs gradually with the level, with no sharp line, and roughly one in five people sits above the level that counts as raised. Lp(a) is also independently associated with calcification and narrowing of the aortic valve, a condition that becomes visible precisely in later life and that is named on almost no patient page.

And then your age enters, because it genuinely changes the conversation. The Dutch guideline on cardiovascular risk management (CVRM/NHG) advises against routinely starting cholesterol-lowering treatment in people over seventy without established cardiovascular disease. A raised Lp(a) at seventy-four therefore does not automatically lead to stricter treatment. Your doctor weighs the result against your overall risk, against the conditions you already have, against your life expectancy and against the number of medicines you already take. Someone on eight tablets a day is not self-evidently better off with a ninth.

There is also something you will rarely read anywhere, but which is true and can bring some peace of mind. Lp(a) predicts damage that builds over decades: the particle has been grinding past your artery wall since childhood. Anyone who reaches seventy or seventy-five without a heart attack has therefore already lived through most of the period in which this number does its work. That is no guarantee for the years ahead, and no reason to ignore the result. But it does put it in proportion: the same number weighs more heavily at thirty than at seventy-five.

What a raised result does change is the attention paid to everything that can still be steered. It is about the number of atherogenic particles passing your artery wall year after year, read from your ApoB and from non-HDL cholesterol rather than from your total cholesterol, and about your blood pressure, your blood sugar and smoking. With a raised Lp(a) you start from a higher point, so keeping those values tight pays off more than it would for a peer without this predisposition. How strict that needs to be is something your doctor decides with you.

Finally, a word about the headlines. Medicines that specifically suppress the production of Lp(a) are in development, and they lower the number steeply. Whether that actually prevents heart attacks has not yet been shown: those outcome trials are still running. Promising is therefore not the same as proven, and there is no drug your doctor can prescribe you for this today.

Lp(a) carries a recommendation you will meet for almost no other blood value: a single measurement in a whole lifetime is enough. The 2022 European consensus advises that one test for every adult. If you have passed fifty, sixty or seventy and Lp(a) has never been measured in you, that is not strange: this value was absent from the standard GP panel for decades, while your cholesterol was drawn faithfully.

Whether that single measurement still makes sense at an older age depends on what you would do with it. If you already have cardiovascular disease, or heart attacks at a young age run in your family, the answer is usually yes. If you have passed eighty, take many medicines and are otherwise in good health, discuss in advance with your GP whether the result would change anything. That is a fairer question than whether you are 'allowed' the test.

Postpone the test during or shortly after an infection, surgery or a hospital admission. Lp(a) behaves partly as an acute-phase protein and then reads temporarily higher; a CRP in the same tube shows whether that is the case. Two conditions that grow more common with the years also lift the value structurally: reduced kidney function (and nephrotic syndrome) and an underactive thyroid. With an unexpectedly high result it is therefore worth having your TSH and your kidney function assessed before any conclusions are drawn. Fasting is not needed for Lp(a); a meal barely shifts the value. If your triglycerides are measured from the same tube, fasting may still be requested: in that case follow the advice you are given at your appointment.

The categories below come from the European consensus. They are intended as orientation, not as a cut-off.

The nmol/l column is emphatically an approximation: because the size of the apo(a) protein differs from person to person, there is no fixed conversion from mg/dl. Weigh your ancestry too, because the average Lp(a) is considerably higher in people of African descent than in people of European or South Asian descent. The same result therefore does not mean the same thing in everyone. Have your doctor place the value within your personal risk profile.